In this study, we retrospectively evaluated the long‐term clinical outcomes of 85 patients newly diagnosed with PCNSL and treated with R‐MPV or HD‐MTX, and further analyzed MYD88 and CD79B status using the droplet digital PCR (ddPCR) method, a highly sensitive genotyping assay, to determine the correlation of MYD88 L265P and CD79B mutations with the prognosis of patients with PCNSL treated with R‐MPV. This evidence concerns the gene MYD88 and primary central nervous system lymphoma.